FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors.
Ontology highlight
ABSTRACT: Fibroblast growth factors (FGFs) and their receptors (FGFRs) have been extensively investigated in solid malignancies, representing an attractive therapeutic target. In breast cancer, especially in estrogen receptor positive (ER+) subtype, FGFR signaling aberrations have been reported to contribute to proliferation, dedifferentiation, metastasis and drug resistance. However, clinical trials evaluating the use of FGFR inhibitors in breast cancer have had disappointing results. The different biological properties of distinct FGFR alterations and lack of established patient selection criteria, in addition to the early use of non-selective inhibitors, are possible reasons of this failure. Herein, we review the current knowledge regarding the role of FGFR signaling in endocrine resistance in br
SUBMITTER: Servetto A
PROVIDER: S-EPMC10537726 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA